Background: Limited research is available concerning therelationship between oxidative stress and inflammationparameters, and simultaneously the effects of rosuvastatinon these markers in patients with hypercholesterolemia.We aimed to investigate the connection between cytokinesand oxidative stress markers in patients with hypercholesterolemia before and after rosuvastatin treatment.Methods: The study consisted of 30 hypercholesterolemic patients diagnosed with routine laboratory testsand 30 healthy participants. The lipid parameters, interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosisfactor-alpha (TNF-α), paraoxonase-1 (PON1) and malondialdehyde (MDA) levels in controls and patients with hypercholesterolemia before and after 12-week treatment withrosuvastatin (10 mg/kg/day), were analyzed by means ofenzyme-linked immunosorbent assay.Results: It was found that a 12-week cure with rosuvastatin resulted in substantial reductions in IL-1β, IL-6 andTNF-α and MDA levels as in rising activities of PON1 inpatients with hypercholesterolemia. Before treatment, thePON1 levels were significantly negatively correlated withTNF-α and IL-6 in control group, while it was positivelycorrelated with TNF-α in patients.Conclusion: Our outcomes provide evidence of protectedeffect of rosuvastatin for inflammation and oxidative damage. It will be of great interest to determine whether thecorrelation between PON1 and cytokines has any phenotypic effect on PON1.